Citadel Advisors
CARM

Citadel Advisors’s Carisma Therapeutics CARM Stock Holding History

Citadel Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,835
Closed -$46.7K – 14762
2022
Q4 		$46.7K Buy
3,835
+510
+15% +$5.36K ﹤0.01% 12217
2022
Q3 		$28K Sell
3,325
-1,555
-32% -$21.2K ﹤0.01% 11935
2022
Q2 		$79K Buy
4,880
+700
+17% +$8.01K ﹤0.01% 11601
2022
Q1 		$50K Sell
4,180
-2,470
-37% -$34.5K ﹤0.01% 12782
2021
Q4 		$108K Sell
6,650
-1,685
-20% -$33.9K ﹤0.01% 12638
2021
Q3 		$132K Sell
8,335
-5,595
-40% -$269K ﹤0.01% 12525
2021
Q2 		$1.29M Buy
13,930
+6,970
+100% +$444K ﹤0.01% 7686
2021
Q1 		$362K Buy
+6,960
New +$328K ﹤0.01% 10411
2020
Q4 		– Sell
-1,785
Closed -$50K – 10939
2020
Q3 		$50K Buy
1,785
+1,160
+186% +$23.2K ﹤0.01% 9605
2020
Q2 		$9K Sell
625
-1,045
-63% -$14.1K ﹤0.01% 9648
2020
Q1 		$19K Sell
1,670
-955
-36% -$15.6K ﹤0.01% 9314
2019
Q4 		$55K Buy
2,625
+905
+53% +$20.8K ﹤0.01% 8728
2019
Q3 		$40K Sell
1,720
-855
-33% -$20K ﹤0.01% 8763
2019
Q2 		$77K Buy
+2,575
New +$77.1K ﹤0.01% 8610
2019
Q1 		– Sell
-560
Closed -$16K – 9288
2018
Q4 		$16K Sell
560
-1,395
-71% -$44.5K ﹤0.01% 8817
2018
Q3 		$84K Sell
1,955
-70
-3% -$2.73K ﹤0.01% 8640
2018
Q2 		$79K Buy
+2,025
New +$89.2K ﹤0.01% 8327

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's CARM Position: Q2 2024 in Review

Citadel Advisors sold out of Carisma Therapeutics (CARM) in Q2 2024, closing a stake of 38,973 shares — an estimated $88.5K sold.

Citadel Advisors first reported a position in CARM in Q3 2016 and held it in 23 quarters. The position peaked at $802K in Q1 2021. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2024.

  • Citadel Advisors reported no remaining Carisma Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 38,973 Carisma Therapeutics shares in Q2 2024, an estimated $88.5K.
  • Citadel Advisors first reported a position in Carisma Therapeutics in Q3 2016 and held it in 23 quarters.
  • Citadel Advisors's Carisma Therapeutics position peaked at $802K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.